enow.com Web Search

Search results

  1. Results from the WOW.Com Content Network
  2. Does The VIVUS, Inc. (NASDAQ:VVUS) Share Price Fall ... - AOL

    www.aol.com/news/does-vivus-inc-nasdaq-vvus...

    For premium support please call: 800-290-4726 more ways to reach us

  3. Why VIVUS Lost in November - AOL

    www.aol.com/news/2012-12-04-why-vivus-lost-in...

    VIVUS' (NAS: VVUS) stock was down 25% for November, though still up 15% for the year. Its drug Qsymia is the first obesity drug to be approved and reach the market in more than a decade, but its ...

  4. VIVUS Obesity Drug Sales Only About 60% of Expectations - AOL

    www.aol.com/news/2013-02-25-vivus-obesity-drug...

    VIVUS Inc. (NASDAQ: VVUS) reported a quarterly loss of $0.56 per share on Monday, but this was not an earnings story. VIVUS remains a developing story about its obesity drug Qsymia. Its revenue ...

  5. VVUS: New Ideas for Established Portfolio

    www.aol.com/news/vvus-ideas-established...

    We are initiating coverage of VIVUS, Inc. (VVUS) with a $10.00 price target based on our revenue forecasts for approved products. In addition to a portfolio of weight loss, exocrine pancreatic ...

  6. Will VIVUS' Strategy Jump-Start Sales? - AOL

    www.aol.com/2012/11/26/will-vivus-strategy...

    Investors had high hopes for VIVUS' (NAS: VVUS) new anti-obesity drug Qsymia, but the drug debuted to lackluster sales -- and it's taking a toll on VIVUS' share price. Now, VIVUS is shifting its ...

  7. Vivus - Wikipedia

    en.wikipedia.org/wiki/Vivus

    Vivus (OTC Pink: VVUSQ) is a small pharmaceutical company headquartered in Campbell, California, working in obesity, sleep, and sexual health.Vivus developed an erectile dysfunction drug, Avanafil, that has completed Phase 3 clinical trials. [1]

  8. Share price - Wikipedia

    en.wikipedia.org/wiki/Share_price

    A corporation can adjust its stock price by a stock split, substituting a quantity of shares at one price for a different number of shares at an adjusted price where the value of shares x price remains equivalent. (For example, 500 shares at $32 may become 1000 shares at $16.) Many major firms like to keep their price in the $25 to $75 price range.

  9. Is a VIVUS Buyout Still on the Table? And if So, by Whom? - AOL

    www.aol.com/news/2012-10-12-is-a-vivus-buyout...

    The pieces of the puzzle are starting to fall into place for VIVUS (NASDAQ: VVUS) and its potential blockbuster anti-obesity drug, Qsymia. The drug, which was approved by the Food and Drug ...